Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01928537
Other study ID # Onconova 04-24
Secondary ID 2013-001124-19
Status Completed
Phase Phase 3
First received
Last updated
Start date August 2013
Est. completion date June 29, 2017

Study information

Verified date July 2018
Source Onconova Therapeutics, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will examine the effect intravenously administered rigosertib has on the relationship between bone marrow blasts response and overall survival in myelodysplastic syndromes (MDS) patients who have 5-30% bone marrow blasts and who progressed on or after treatment with azacitidine or decitabine.


Recruitment information / eligibility

Status Completed
Enrollment 67
Est. completion date June 29, 2017
Est. primary completion date June 29, 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Diagnosis of MDS confirmed within 6 weeks prior to Screening according to WHO criteria or French-American-British (FAB) classification.

- MDS classified as follows, according to WHO criteria and FAB classification:

- RAEB-1 (5% to 9% BM blasts)

- RAEB-2 (10% to 19% BM blasts)

- CMML (10% to 20% BM blasts) and white blood cells (WBC) < 13,000/µL

- RAEB-t (20% to 30% BM blasts), meeting the following criteria: WBC < 25,000/µL at study entry; or, Stable White Blood Cell (WBC) at least 4 weeks prior to Screening and not requiring intervention for WBC control with hydroxyurea, chemotherapy, or leukopheresis.

- At least one cytopenia (Absolute Neutrophil Count (ANC) < 1800/µL or Platelet (PLT) count < 100,000/µL or hemoglobin (Hgb) < 10 g/dL).

- Progression (according to 2006 IWG criteria) at any time after initiation of subcutaneous or intravenous azacitidine or decitabine treatment per labeling during the past 2 years, defined as follows:

- For patients with ? 5% BMBL, = 50% increase in BMBL to ? 5% BMBL

- For patients with 5-10% BMBL, = 50% increase in BMBL to ? 10% BMBL

- For patients with 10-20% BMBL, = 50% increase in BMBL to ? 20% BMBL

- For patients with 20-30% BMBL, = 50% increase in BMBL to ? 30% BMBL

- Any of the following: = 50% decrease from maximum remission/response levels in granulocytes or PLT; Decrease in Hgb concentration by = 2 g/dL; or, Transfusion dependence, defined as administration of at least 4 RBC units in the past 8 weeks before Screening (patients must have Hgb values ? 9 g/dL prior to transfusion to be considered), in the absence of another explanation.

- Has failed to respond to, relapsed following, not eligible, or opted not to participate in bone marrow transplantation.

- Off all other treatments for MDS for at least 4 weeks, except for azacitidine or decitabine. Filgrastim (G-CSF) and erythropoietin are allowed before and during the study as clinically indicated.

- No medical need for induction chemotherapy.

- Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2.

- Willing to adhere to the prohibitions and restrictions specified in this protocol.

- Patient must signed an informed consent form.

Exclusion Criteria:

- Previous participation in a clinical study of IV or oral rigosertib.

- Anemia due to factors other than MDS (including hemolysis or gastrointestinal [GI] bleeding) unless stabilized for 1 week after RBC transfusion.

- Any active malignancy within the past year, except basal cell or squamous cell skin cancer or carcinoma in situ of the cervix or breast.

- Uncontrolled intercurrent illness including.

- Active infection not adequately responding to appropriate therapy.

- Total bilirubin = 1.5 mg/dL not related to hemolysis or Gilbert's disease.

- ALT/AST = 2.5 x upper limit of normal (ULN).

- Serum creatinine = 2.0 mg/dL.

- Ascites requiring active medical management including paracentesis, or hyponatremia (defined as serum sodium value of <130 mEq/L).

- Female patients who are pregnant or lactating.

- Patients who are unwilling to follow strict contraception requirements.

- Female patients with reproductive potential who do not have a negative urine beta-human chorionic gonadotropin (ßHCG) pregnancy test at Screening.

- Major surgery without full recovery or major surgery within 3 weeks of Baseline/Cycle 1 Day 1 visit.

- Uncontrolled hypertension (defined as a systolic pressure =160 mmHg and/or a diastolic pressure = 110 mmHg).

- New onset seizures (within 3 months prior to Baseline) or poorly controlled seizures.

- Any other concurrent investigational agent or chemotherapy, radiotherapy, or immunotherapy.

- Prior treatment with low-dose cytarabine during the past 2 years.

- Investigational therapy within 4 weeks of Baseline/Day 1 visit.

- Psychiatric illness or social situation that would limit the patient's ability to tolerate and/or comply with study requirements.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
rigosertib sodium


Locations

Country Name City State
Australia Royal Adelaide Hospital Adelaide South Australia
Australia Monash Health, Monash Medical Centre Clayton Victoria
Australia Peter MacCallum Cancer Center East Melbourne Victoria
Australia Royal Melbourne Hospital Parkville Victoria
Denmark Aarhus University Hospital Aarhus Jylland
Denmark Rigshospitalet, Department of Hematology Copenhagen Hovedstaden
France Institute Paoli Calmettes Marseille
France Hôpital Saint-Louis, Service d'Hématologie Paris IDF
Germany University Hospital Carl Guslav Carus Dresden
Germany Marien Hospital, Onkologie Düsseldorf
Germany Universitätsklinikum Frankfurt, Goethe Universität Frankfurt Hessen
Germany Universitätsmedizin Göttingen Göttingen
Germany Universitätsklinikum Köln Klinik I für Innere Medizin Köln
Germany Technische Universität München, III. Medizinische Klinik München
Italy Azienda Ospedaliero-Universitaria Careggi Firenze
Italy AOU Maggiore della Carità, SCUD Ematologia Novara
Italy Policlinico Umberto 1, Universita "Sapienza" Rome
Spain Hospital Universitário de Salamanca Salamanca
Sweden Sahlgrenska University Hospital Gothenberg Västra Götalandsregionen
Sweden Skåne University Hospital, Lund Skåne
Sweden Karolinska University Hospital, Huddinge Stockholm
United States Greenbaum Cancer Center University of Maryland Baltimore Maryland
United States Dana Farber Cancer Institute Boston Massachusetts
United States Montefiore Medical Center Bronx New York
United States Rush University Medical Center Chicago Illinois
United States University of Chicago Medicine Chicago Illinois
United States University of Texas Southwestern Medical Center Dallas Texas
United States University of Texas Southwestern Medical Center-Parkland Hospital Dallas Texas
United States MD Anderson Cancer Center Houston Texas
United States Columbia University Medical Center New York New York
United States Mount Sinai Medical Center New York New York
United States New York Presbyterian Hospital-Weill Cornell Medical College New York New York
United States Mayo Clinic Rochester Minnesota
United States Stanford University Cancer Center Stanford California
United States University of Kansas Cancer Center and Medical Pavilion Westwood Kansas

Sponsors (1)

Lead Sponsor Collaborator
Onconova Therapeutics, Inc.

Countries where clinical trial is conducted

United States,  Australia,  Denmark,  France,  Germany,  Italy,  Spain,  Sweden, 

References & Publications (5)

Al-Kali A. Relationship of bone marrow blast (BMBL) response to overall survival (OS) in a multicenter study of rigosertib (Rigo) in patients (pts) with myelodysplastic syndrome (MDS) with excess blasts progressing on or after treatment with a hypomethyla

Garcia-Manero G, Fenaux P. Comprehensive Analysis of Safety: Rigosertib in 557 Patients with Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML). Blood Dec 2016, 128 (22) 2011; ASH 2016.

Olnes MJ, Shenoy A, Weinstein B, Pfannes L, Loeliger K, Tucker Z, Tian X, Kwak M, Wilhelm F, Yong AS, Maric I, Maniar M, Scheinberg P, Groopman J, Young NS, Sloand EM. Directed therapy for patients with myelodysplastic syndromes (MDS) by suppression of cyclin D1 with ON 01910.Na. Leuk Res. 2012 Aug;36(8):982-9. doi: 10.1016/j.leukres.2012.04.002. Epub 2012 Apr 21. — View Citation

Seetharam M, Fan AC, Tran M, Xu L, Renschler JP, Felsher DW, Sridhar K, Wilhelm F, Greenberg PL. Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na. Leuk Res. 2012 Jan;36(1):98-103. doi: 10.1016/j.leukres.2011.08.022. Epub 2011 Sep 14. — View Citation

Silverman LR, Greenberg P, Raza A, Olnes MJ, Holland JF, Reddy P, Maniar M, Wilhelm F. Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy. Hematol Oncol. 2015 Jun;33(2):57-66. doi: 10.1002/hon.2137. Epub 2014 Apr 29. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Relationship of bone marrow blast response and overall survival. Bone marrow blast response is defined as bone marrow (BM) complete response, = 50% BM blast decrease from pretreatment value, or stable BM response (no progression) according to the International Working Group (IWG) 2006 criteria and overall survival. Overall survival is defined as the time from first study treatment to death from any cause. All patients will be followed until death and/or progression, even if they have discontinued treatment for whatever cause. Survival time of patients lost to follow-up will be censored at the time they were last known to be alive. Up to 2 years.
Secondary Number of patients with overall hematologic response. Overall hematologic response (complete remission [CR], partial remission [PR], bone marrow complete response [BMCR], and stable disease [SD]) is defined according to 2006 International Working Group (IWG) response criteria. Up to 2 years after study enrollment.
Secondary Number of patients with hematological improvement. Hematological improvement (erythroid response, platelet response and neutrophil response) is defined according to 2006 International Working Group (IWG) response criteria. Up to 2 years after study enrollment.
Secondary Number of patients with cytogenetic response. Cytogenetic response is defined according to 2006 International Working Group (IWG) response criteria. Up to 2 years after study enrollment.
Secondary Progression-free survival. Progression-free survival is defined as time from date of first dose until date when progression is documented. Progression is defined according to 2006 International Working Group (IWG) response criteria. Up to 2 years after study enrollment.
Secondary Number of patients who transition to Acute Myeloid Leukemia (AML) Participants who progress to Acute Myeloid Leukemia (AML) during the study. AML is defined as an increase of at least 50% bone marrow blasts, and more than 20% bone marrow blasts for Refractory Anemia with Excess Blasts types 1 and 2 (RAEB-1 and RAEB-2) and Chronic Myelomonocytic Leukemia (CMML) patients and as an increase of at least 50% bone marrow blasts for Refractory Anemia with Excess Blasts in Transformation (RAEB-t) patients. Up to 2 years after study enrollment.
Secondary Quality of Life Questionnaire Change from baseline in responses in the European Organization for Research and Treatment of Cancer [EORTC] Quality of Life Questionnaire [QLQ]-C30 version 3. Questionnaire will be administered at baseline and at 4 week intervals. Up to 2 years after study enrollment.
Secondary Infections. Incidence of infections requiring treatment with intravenous antimicrobials and of bleeding episodes. Up to 2 years after study enrollment.
Secondary Concentration of rigosertib in plasma. Concentration of rigosertib in plasma will be measured by a validated High Performance Liquid Chromatography (HPLC) method. Week 1 and week 3.
Secondary Safety. Counts of patients who have adverse events (AEs). Adverse events will be grouped by system organ class (SOC) and preferred term (PT) using the most recent version of the Medical Dictionary for Regulatory Activities (MedDRA), and will be summarized by worst grade according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0. Study enrollment until 30 days after patient's last dose of rigosertib up to 2 years.
See also
  Status Clinical Trial Phase
Recruiting NCT05400122 - Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer Phase 1
Terminated NCT04313881 - Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS) Phase 3
Recruiting NCT05088356 - Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft Phase 1
Recruiting NCT04003220 - Idiopathic Chronic Thrombocytopenia of Undetermined Significance : Pathogenesis and Biomarker
Completed NCT02916979 - Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG Phase 1
Active, not recruiting NCT03755414 - Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation Phase 1
Completed NCT00003270 - Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer Phase 2
Recruiting NCT04904588 - HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide Phase 2
Terminated NCT04866056 - Jaktinib and Azacitidine In Treating Patients With MDS With MF or MDS/MPN With MF. Phase 1/Phase 2
Recruiting NCT04701229 - Haploinsufficiency of the RBM22 and SLU7 Genes in Del(5q) Myelodysplastic Syndromes
Suspended NCT04485065 - Safety and Efficacy of IBI188 With Azacitidine in Subjects With Newly Diagnosed Higher Risk MDS Phase 1
Recruiting NCT04174547 - An European Platform for Translational Research in Myelodysplastic Syndromes
Enrolling by invitation NCT04093570 - A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose), With a Food Effect Substudy at Select Study Centers Phase 2
Completed NCT02508870 - A Study of Atezolizumab Administered Alone or in Combination With Azacitidine in Participants With Myelodysplastic Syndromes Phase 1
Completed NCT04543305 - A Study of PRT1419 in Patients With Relapsed/Refractory Hematologic Malignancies Phase 1
Recruiting NCT05384691 - Efficacy of Luspatercept in ESA-naive LR-MDS Patients With or Without Ring Sideroblasts Who do Not Require Transfusions Phase 2
Recruiting NCT05365035 - A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts Phase 2
Recruiting NCT06008405 - Clinical Trial Evaluating the Safety of the TQB2928 Injection Combination Therapy Phase 1
Not yet recruiting NCT05969821 - Clonal Hematopoiesis of Immunological Significance
Withdrawn NCT05170828 - Cryopreserved MMUD BM With PTCy for Hematologic Malignancies Phase 1